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Reports of human infection with Plasmodium knowlesi, 
a monkey malaria, suggest that it and other nonhuman ma-
laria species may be an emerging health problem. We report 
the use of a rapid test to supplement microscopic analysis in 
distinguishing the 5 malaria species that infect humans.
R
ecent reports of Plasmodium knowlesi infections in 
humans in Sarawak and Sabah in Borneo and in the 
Pahang Peninsula of Malaysia have focused attention on 
the potential of monkey malarias to be a human health is-
sue (1,2). As much as 70% of malaria infections in regional 
hospitals in Borneo are the result of P. knowlesi infection; 
similar infections have been found in Thailand, the Philip-
pines, and Singapore (3–5). To date, only patients in hospi-
tals are being screened for the disease. To better understand 
the epidemiology of this apparent outbreak of P. knowlesi 
in humans, one needs a method to rapidly screen both mon-
keys and humans in areas of high disease prevalence, re-
gardless of their present health status. Thus, a rapid test that 
could detect and distinguish among the primate malarias 
would not only beneﬁ  t individual patients but would also 
provide an important epidemiologic tool to monitor the 
overall risk and prevalence of malaria.
We have known for nearly 8 decades that, under labo-
ratory conditions, several monkey malarias are capable of 
infecting humans and that P. knowlesi can be transmit-
ted to humans by mosquito bite (6,7). Work in Malaysia 
by a team from the National Institutes of Health nearly 
50 years ago reported that transmission to humans was 
not occurring to any prevalent extent. Currently, we see 
major foci of the disease, which can be life-threatening. 
Although the current overall incidence of P. knowlesi 
infection in humans is low, an exacerbating problem is 
that it can be consistently misdiagnosed by microscopy 
as the more benign human malaria, P. malariae (1,2,8,9). 
The rapid replication rate of P. knowlesi and the resulting 
high level of parasitemia warrant immediate and aggres-
sive treatment, whereas P. malariae does not. Although 
the use of PCR has been essential to deﬁ  ning the problem, 
a more rapid diagnosis would be an important tool for 
prompt medical treatment. Furthermore, incorporating the 
capability to detect P. knowlesi into existing rapid tests 
already capable of detecting the other 4 Plasmodium spe-
cies that infect humans (P. falciparum, P. vivax, P. ovale, 
and P. malariae) would be beneﬁ  cial.
P. knowlesi is transmitted by members of the Anoph-
eles leucosphyrus group of mosquitoes that resides in the 
upper canopy of the forests in large areas of Southeast 
Asia; these Anopheles  mosquitoes have infrequent con-
tact with humans (10). With increasing encroachment into 
the forest areas to provide farmland, however, humans are 
likely to increase their exposure to this vector. The poten-
tial for P. knowlesi infection as well as other monkey ma-
larias to expand into the human population is real. While 
the P. knowlesi parasite is carried by zoophilic mosquitoes, 
some monkey malarias such as P. cynomolgi and P. inui are 
transmitted by the same mosquito vectors that carry human 
malaria and therefore represent an even wider threat. 
One important test developed for detecting human 
malarias is an antigen-capture test based on monoclonal 
antibodies (MAbs) to plasmodium lactate dehydrogenase 
(pLDH). The 4 human malarial LDH isoforms have been 
cloned, and >20 MAbs have been raised that differentially 
recognize epitopes among the isoforms (11,12). The speci-
ﬁ  city of a subset of these antibodies is shown in Figure 1. 
Of the 4 human Plasmodium spp., antibodies such as 17E4 
and 7G9 speciﬁ   cally bind only to P. falciparum LDH, 
whereas antibodies such as 11D9 and 13H11 bind only to 
P. vivax LDH.
Using this panel of antibodies, we show that we can 
distinguish  P. knowlesi from P. malariae.  P. knowlesi 
binds to both the “falciparum-speciﬁ  c” (17E4/7G9) and the 
“vivax-speciﬁ  c” (11D9/13H11) antibodies (Figure 1, pan-
els A and B). Furthermore, P. knowlesi does not react with 
10D12 (an antibody speciﬁ  c for P. ovale), 7E7 (an antibody 
that reacts strongly with P. malariae and weakly with P. 
falciparum), or 9C1 (an antibody that reacts exclusively 
with P. ovale and P. malariae). Detecting P. knowlesi in 
monkeys, which often are co-infected with several other 
malaria parasites, is also important and can be achieved 
with the same panel of antibodies. We have tested the re-
activity of the P. falciparum–speciﬁ  c antibody (17E4/7G9) 
with the other monkey malarias known to be indigenous to 
Malaysia (P. cynomolgi, P. inui, and P. ﬁ  eldi) and found 
that none react (Figure 1, panel C). This then serves as a ba-
sis for distinguishing P. knowlesi from the other prevalent 
forms of monkey malaria.
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The unexpected pattern of antibody recognition on 
which we based our tests led us to examine the molecular 
basis of recognition (Figure 2). As expected, P. knowlesi 
LDH is highly similar to the known pLDH isoforms. We 
found that only a few residue differences could account 
for the epitope differences detected by the 17E4/7G9 and 
11D9/13H11 antibodies. We ﬁ  rst generated a 3-dimension-
al model of P. knowlesi LDH and then mapped surface-ex-
posed residues that were uniquely shared by P. falciparum 
or P. vivax isoforms. The protein structure was calculated 
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Figure 1. Binding speciﬁ  city of different anti–Plasmodium lactate dehydrogenase (pLDH) antibodies. A) Shown are the reactivities of the 
indicated monoclonal antibodies (MAbs) to the LDH from 7 Plasmodium spp. Reactivity was determined by using an immunocapture 
assay as previously described (9). B) Example of an immunodipstick assay that detects P. knowlesi. An immunochromatographic strip 
assay containing the indicated antibodies was allowed to wick lysed blood infected with P. vivax, P. falciparum, P. knowlesi, P. ovale, or P. 
malariae. Blood was wicked in the presence of colloidal gold conjugated to antibody 6C9, which binds all pLDH isoforms. P. vivax LDH is 
immobilized only by 11D9 and 13H11, and P. falciparum LDH was only immobilized by 17E4. P. knowlesi LDH was immobilized by 11D9 
and 13H11 antibodies and also by 17E4. C) An immunochromatographic strip assay containing the indicated antibodies was allowed to 
wick lysed blood infected with P. vivax, P. cynomolgi, P. inui, and P. knowlesi. Blood was wicked in the presence of colloidal gold conjugated 
to antibody 6C9, which binds all pLDH isoforms. Both P. cynomolgi and P. inui show the same epitope proﬁ  le as P. vivax.
Figure 2. Modeling of the analysis of Plasmodium knowlesi lactate dehydrogenase (LDH). A) Sequence of LDH from P. knowlesi deduced 
from genomic DNA fragments sequenced by the Sanger malaria genome project (www.sanger.ac.uk/Projects/P_knowlesi). LDH isoforms 
from P. vivax, P. malariae, P. ovale, P. berghei, P. yoelli, and P. falciparum were compared with that of P. knowlesi. Residues unique to P. 
knowlesi and P. vivax are shown in blue; residues unique to P. knowlesi and P. falciparum are shown in red. B) Model of P. knowlesi LDH 
and speciﬁ  c epitopes. A model for P. knowlesi LDH was calculated by using WURST protein threading server (www.zbh.uni-hamburg.de/
wurst/index.php)  and the P. falciparum and P. vivax crystal structures (PDB: 2A94 and 3 2AA3). Shown is the monomer, as well as the 
assembled tetramer, aligned to the backbone of the P. vivax tetramer using pymol. The nicotinamide adenine dinucleotide cofactor analog 
3-acetyl pyridine adenine dinucleotide is shown in black. Residues important for substrate binding and catalysis are shown in yellow. P. 
knowlesi residues shared only with P. vivax are shown in blue and indicate where the 11D9/13H11 epitopes could be. P. knowlesi residues 
shared only with P. falciparum are shown in red and indicate a critical determinant of the 17E4/7G9 epitopes.by using the structures of P. falciparum and P. vivax LDH 
(PDB: 2A94 and 2AA3) and the WURST threading server 
(13). Here, only a few patches of residues were found to 
describe the P. vivax–speciﬁ  c epitope, and only 1 residue 
(K115) was found to describe the P. falciparum–speciﬁ  c 
epitope (Figure 2, panel B). Thus, the existing MAbs per-
form well at distinguishing pLDH isoforms despite only a 
small number of different surface-exposed residues.
These data show that pLDH antibodies that detect P. 
falciparum and P. vivax can also be used to detect and dis-
tinguish P. knowlesi. The 1 major caveat is that a P. knowle-
si infection cannot be distinguished from a mixed infection 
with both P. vivax and P. falciparum in the blood. Mixed 
infections of this description, however, are infrequent, as 
these species do not proliferate concurrently when both are 
present in the blood (14,15). Furthermore, any confusion 
would be resolved by microscopic examination of blood 
that, while inadequate to distinguish P. knowlesi and P. ma-
lariae, would serve to distinguish P. knowlesi from mixed 
infections.
Obviously, an antibody speciﬁ  c for P. knowlesi would 
be optimal if the threat of P. knowlesi increases. Although 
development of a speciﬁ  c antibody would be a considerable 
investment, our epitope analysis discussed here indicates 
that only small sequence differences in pLDH isoforms are 
required to generate antibody panels capable of uniquely 
distinguishing animal pLDH isoforms.
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